Day: May 1, 2024

Tel Aviv, Israel, May 1, 2024 — Arbe Robotics Ltd. (Nasdaq: ARBE) (“Arbe”), a global leader in Perception Radar Solutions, today announced that it will hold its first quarter conference call on Wednesday, March 22 at 8:30 a.m. Eastern Time. The company will issue its financial results before the market opens that same day. Conference Call and Webcast Details Speakers will include Kobi Marenko, Co-Founder and Chief Executive Officer and Karine Pinto-Flomenboim, Chief Financial Officer. The live call may be accessed via telephone at (844) 481-3015 toll-free, (80) 921-2373 Israel toll-free, or (412) 317-1880 internationally. A telephonic replay of the conference call will be available following the end of the conference call until June 5, 2024. To listen to the replay, please dial (877) 344-7529, or (412) 317-0088 internationally, using access...

DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and use the conference ID 2270373. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. About Avadel Pharmaceuticals plcAvadel...

SINGAPORE, May 01, 2024 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company“), an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore, has engaged Strategic Investor Relations, a premier investor relations firm, to enhance Primech’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the company’s growth and strategic initiatives. With this new partnership, Primech aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the company’s progress and prospects. Strategic Investor Relations will assist Primech in highlighting its innovative solutions,...

An Intouch Insight study has found that 7 out of 10 brands’ innovation experiences outperformed the legacy experiences. The investment made in these new restaurant prototypes, like Burger King’s Sizzle, Taco Bell’s Go Mobile, and Wendy’s Global NextGen, has resulted in notable improvements to key customer experience metrics. Ottawa, Ontario, May 01, 2024 (GLOBE NEWSWIRE) — Intouch Insight, a well-known provider of customer experience management solutions in North America, has released the second edition of its Emerging Experience study today in partnership with QSR® Magazine. The report, Next-Gen Restaurant Experiences: The Rise of Innovative Locations, is focused on how technology is impacting the customer experience for multi-location QSR brands. “We have been closely monitoring the latest trends in the...

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligoBRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced two abstracts reporting results for its novel BET inhibitor, VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA. “We look forward to sharing our preclinical and Phase 1b data for VYN201 with researchers and clinicians at the upcoming SID Annual Meeting,” said Iain Stuart, Ph.D., Chief Scientific Officer...

The largest Association in the state of Michigan makes FOREWARN services available for its 7,500+ real estate professional members to promote proactive agent safety BOCA RATON, Fla., May 01, 2024 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Greater Metropolitan Association of REALTORS® (“GMAR”) will offer FOREWARN® services to its 7,500+ members it serves throughout Macomb, Oakland, and Wayne County in metro-Detroit to promote proactive real estate agent safety. Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided...

– CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study – – Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th– SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations....

VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This historic shift, pending review by the White House Office of Management and Budget (OMB), recognizes the medical utility of cannabis and its lower potential for abuse compared to substances in higher schedules. HYTN views this as a progressive move which harmonizes federal regulations with the evolving public and medical stance on cannabis. HYTN notes that such a change...

SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following May investor events.RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, May 14, 2024, at 1:35 p.m. Eastern Time. Stifel West Coast Bus Tour Members of Pliant’s senior management team will meet with investors on Thursday, May 23, 2024, as part of an invitation-only event hosted by Stifel. Piper Sandler Virtual Lung Investor Day Keith Cummings, M.D., Pliant’s Chief...